Oral semaglutide (Rybelsus), a GLP-1 agonist, reduced heart failure events in patients with type 2 diabetes who had a history of heart failure and either atherosclerotic cardiovascular disease, chronic kidney disease, or both. The SOUL study showed that this drug reduced the risk of cardiovascular death, myocardial infarction, and stroke by 14% compared to placebo in patients at high cardiovascular risk. Oral semaglutide significantly reduces hospitalizations related to serious adverse events compared with placebo. The previous PIONEER 6 study confirmed the cardiovascular safety of oral semaglutide in 3183 patients with type 2 diabetes over 50 years of age, with a 21% reduction in major cardiovascular events. These events included death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke. The results of the SOUL study were presented at a meeting of the European Association for the Study of Diabetes.[2][5]